2025 Q3 -tulosraportti
50 päivää sittenTarjoustasot
Nasdaq Copenhagen
Määrä
Osto
19 376
Myynti
Määrä
2 671
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 671 | - | - | ||
| 45 000 | - | - | ||
| 22 866 | - | - | ||
| 17 124 | - | - | ||
| 112 339 | - | - |
Ylin
0,112VWAP
Alin
0,081VaihtoMäärä
0,1 603 293
VWAP
Ylin
0,112Alin
0,081VaihtoMäärä
0,1 603 293
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 14.5. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 14.8.2025 | |
| 2025 Q1 -tulosraportti | 15.5.2025 | |
| 2024 Q4 -tulosraportti | 20.3.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·30.12.2025It could very well suddenly take off :) RNX-051 -- Advanced partnership dialogues PEG is engaged in advanced and constructive dialogues with potential industrial partners regarding RNX-051. The discussions include structures that could lead to a license or partnership agreement, and the company expects to conclude these negotiations in H1 2026. The dialogues include relevant clinical, regulatory, and industrial collaborations, including relationships with clinical sites, local regulatory partners, and potential industrial collaborators, with the aim of supporting a robust study design and a future partnership and licensing process. A conclusion of the negotiations will constitute the first significant milestone towards a final license agreement and thus a crucial step in realizing RNX-051's commercial potential. At the same time, the finalization of the final study protocols for RNX-051 is underway. The protocols are currently available in a sub-final draft and comprise an international, multicenter clinical study. In connection with the planning, the company has worked purposefully to identify and address significant regulatory and operational barriers to the implementation of international clinical studies with RNX-051. The company can report that these barriers have now been overcome, that the study structure and timeline have been established, and that no significant obstacles to the implementation of the study have been identified at this time. These protocols are considered to be the last necessary studies that potential license and collaboration partners in the ongoing dialogues are expected to request before entering into an agreement. RNX-011 -- Strategic further development For RNX-011, which is aimed at the treatment of peritonitis, significant progress has been made, and the company has established a clear and targeted strategy for its further development. The clinical study protocol for RNX-011 is, as previously announced, already approved. In this regard, the protocol is undergoing targeted adjustments with the aim of sharpening the study design in relation to expectations and requirements from potential license and collaboration partners, including a particular focus on ensuring that the clinical endpoints clearly reflect the observed treatment response and thereby support the project's differentiation and licensing attractiveness. As previously announced, RNX-011 has shown promising results within the indication peritonitis. Based on these results, the company is working purposefully to ensure that the approved study design supports the project's attractiveness and value creation in a future licensing process to the greatest extent possible. The completed and planned activities are collectively assessed to constitute the last necessary studies before the company expects to initiate actual license dialogues. The strategy aims to: ● ensure further improved data and results, ● strengthen the project's attractiveness to potential license partners, and ● maximize the potential shareholder value from future agreements. Otiom Dialogues regarding the Otiom business continue to proceed satisfactorily and in accordance with the company's strategic objectives. No further details can be provided at this time. Overall assessment The Board of Directors and management assess that the chosen strategy -- including the renunciation of short-term revenue -- is the most responsible and value-creating approach for shareholders. While RNX-051 is currently in active and advanced partner dialogues, the company for RNX-011 focuses on further value creation through targeted development prior to the licensing process. PEG continues to stand on a solid strategic foundation with: a focused pipeline advanced dialogues regarding RNX-051, a clear development strategy for RNX-011, and an unambiguous goal of realizing maximum long-term value through partnerships and license agreements. The company will continuously keep the market updated on significant progress. For further information, contact: Christian Tange, CEO, Pharma Equity Group A/S, telephone: +45 2948 8417, e-mail: ct@pharmaequitygroup.com Christian Vinding Thomsen, Chairman of the Board, Pharma Equity Group A/S, telephone: +45 2622 7222, e-mail: cvt@loevenlaw.dk About Pharma Equity Group A/S Pharma Equity Group A/S is a listed company on Nasdaq Copenhagen that focuses on early investment in and development of Life Science companies with great potential. The company's strategic focus is to act as an active consolidator within the areas of Pharma, MedTech, and Medical Devices, with a particular eye for Nordic innovation that addresses significant unmet medical needs. Through an actively managed portfolio, which includes the wholly-owned subsidiary Reponex Pharmaceuticals A/S, Pharma Equity Group works to create value by providing capital, strategic management, and industry-specific expertise to its portfolio companies. The goal is to bring groundbreaking healthcare solutions quickly
·12.12.2025What do you others think about Otiom possibly being acquired now?2 ääntä PäättynytLiity Sharevilleen nähdäksesi tuloksetMakes sense50%Makes no sense50%Complete disaster0%Other0%
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
50 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·30.12.2025It could very well suddenly take off :) RNX-051 -- Advanced partnership dialogues PEG is engaged in advanced and constructive dialogues with potential industrial partners regarding RNX-051. The discussions include structures that could lead to a license or partnership agreement, and the company expects to conclude these negotiations in H1 2026. The dialogues include relevant clinical, regulatory, and industrial collaborations, including relationships with clinical sites, local regulatory partners, and potential industrial collaborators, with the aim of supporting a robust study design and a future partnership and licensing process. A conclusion of the negotiations will constitute the first significant milestone towards a final license agreement and thus a crucial step in realizing RNX-051's commercial potential. At the same time, the finalization of the final study protocols for RNX-051 is underway. The protocols are currently available in a sub-final draft and comprise an international, multicenter clinical study. In connection with the planning, the company has worked purposefully to identify and address significant regulatory and operational barriers to the implementation of international clinical studies with RNX-051. The company can report that these barriers have now been overcome, that the study structure and timeline have been established, and that no significant obstacles to the implementation of the study have been identified at this time. These protocols are considered to be the last necessary studies that potential license and collaboration partners in the ongoing dialogues are expected to request before entering into an agreement. RNX-011 -- Strategic further development For RNX-011, which is aimed at the treatment of peritonitis, significant progress has been made, and the company has established a clear and targeted strategy for its further development. The clinical study protocol for RNX-011 is, as previously announced, already approved. In this regard, the protocol is undergoing targeted adjustments with the aim of sharpening the study design in relation to expectations and requirements from potential license and collaboration partners, including a particular focus on ensuring that the clinical endpoints clearly reflect the observed treatment response and thereby support the project's differentiation and licensing attractiveness. As previously announced, RNX-011 has shown promising results within the indication peritonitis. Based on these results, the company is working purposefully to ensure that the approved study design supports the project's attractiveness and value creation in a future licensing process to the greatest extent possible. The completed and planned activities are collectively assessed to constitute the last necessary studies before the company expects to initiate actual license dialogues. The strategy aims to: ● ensure further improved data and results, ● strengthen the project's attractiveness to potential license partners, and ● maximize the potential shareholder value from future agreements. Otiom Dialogues regarding the Otiom business continue to proceed satisfactorily and in accordance with the company's strategic objectives. No further details can be provided at this time. Overall assessment The Board of Directors and management assess that the chosen strategy -- including the renunciation of short-term revenue -- is the most responsible and value-creating approach for shareholders. While RNX-051 is currently in active and advanced partner dialogues, the company for RNX-011 focuses on further value creation through targeted development prior to the licensing process. PEG continues to stand on a solid strategic foundation with: a focused pipeline advanced dialogues regarding RNX-051, a clear development strategy for RNX-011, and an unambiguous goal of realizing maximum long-term value through partnerships and license agreements. The company will continuously keep the market updated on significant progress. For further information, contact: Christian Tange, CEO, Pharma Equity Group A/S, telephone: +45 2948 8417, e-mail: ct@pharmaequitygroup.com Christian Vinding Thomsen, Chairman of the Board, Pharma Equity Group A/S, telephone: +45 2622 7222, e-mail: cvt@loevenlaw.dk About Pharma Equity Group A/S Pharma Equity Group A/S is a listed company on Nasdaq Copenhagen that focuses on early investment in and development of Life Science companies with great potential. The company's strategic focus is to act as an active consolidator within the areas of Pharma, MedTech, and Medical Devices, with a particular eye for Nordic innovation that addresses significant unmet medical needs. Through an actively managed portfolio, which includes the wholly-owned subsidiary Reponex Pharmaceuticals A/S, Pharma Equity Group works to create value by providing capital, strategic management, and industry-specific expertise to its portfolio companies. The goal is to bring groundbreaking healthcare solutions quickly
- ·12.12.2025What do you others think about Otiom possibly being acquired now?2 ääntä PäättynytLiity Sharevilleen nähdäksesi tuloksetMakes sense50%Makes no sense50%Complete disaster0%Other0%
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
19 376
Myynti
Määrä
2 671
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 671 | - | - | ||
| 45 000 | - | - | ||
| 22 866 | - | - | ||
| 17 124 | - | - | ||
| 112 339 | - | - |
Ylin
0,112VWAP
Alin
0,081VaihtoMäärä
0,1 603 293
VWAP
Ylin
0,112Alin
0,081VaihtoMäärä
0,1 603 293
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 14.5. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 14.8.2025 | |
| 2025 Q1 -tulosraportti | 15.5.2025 | |
| 2024 Q4 -tulosraportti | 20.3.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
50 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 14.5. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 14.8.2025 | |
| 2025 Q1 -tulosraportti | 15.5.2025 | |
| 2024 Q4 -tulosraportti | 20.3.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·30.12.2025It could very well suddenly take off :) RNX-051 -- Advanced partnership dialogues PEG is engaged in advanced and constructive dialogues with potential industrial partners regarding RNX-051. The discussions include structures that could lead to a license or partnership agreement, and the company expects to conclude these negotiations in H1 2026. The dialogues include relevant clinical, regulatory, and industrial collaborations, including relationships with clinical sites, local regulatory partners, and potential industrial collaborators, with the aim of supporting a robust study design and a future partnership and licensing process. A conclusion of the negotiations will constitute the first significant milestone towards a final license agreement and thus a crucial step in realizing RNX-051's commercial potential. At the same time, the finalization of the final study protocols for RNX-051 is underway. The protocols are currently available in a sub-final draft and comprise an international, multicenter clinical study. In connection with the planning, the company has worked purposefully to identify and address significant regulatory and operational barriers to the implementation of international clinical studies with RNX-051. The company can report that these barriers have now been overcome, that the study structure and timeline have been established, and that no significant obstacles to the implementation of the study have been identified at this time. These protocols are considered to be the last necessary studies that potential license and collaboration partners in the ongoing dialogues are expected to request before entering into an agreement. RNX-011 -- Strategic further development For RNX-011, which is aimed at the treatment of peritonitis, significant progress has been made, and the company has established a clear and targeted strategy for its further development. The clinical study protocol for RNX-011 is, as previously announced, already approved. In this regard, the protocol is undergoing targeted adjustments with the aim of sharpening the study design in relation to expectations and requirements from potential license and collaboration partners, including a particular focus on ensuring that the clinical endpoints clearly reflect the observed treatment response and thereby support the project's differentiation and licensing attractiveness. As previously announced, RNX-011 has shown promising results within the indication peritonitis. Based on these results, the company is working purposefully to ensure that the approved study design supports the project's attractiveness and value creation in a future licensing process to the greatest extent possible. The completed and planned activities are collectively assessed to constitute the last necessary studies before the company expects to initiate actual license dialogues. The strategy aims to: ● ensure further improved data and results, ● strengthen the project's attractiveness to potential license partners, and ● maximize the potential shareholder value from future agreements. Otiom Dialogues regarding the Otiom business continue to proceed satisfactorily and in accordance with the company's strategic objectives. No further details can be provided at this time. Overall assessment The Board of Directors and management assess that the chosen strategy -- including the renunciation of short-term revenue -- is the most responsible and value-creating approach for shareholders. While RNX-051 is currently in active and advanced partner dialogues, the company for RNX-011 focuses on further value creation through targeted development prior to the licensing process. PEG continues to stand on a solid strategic foundation with: a focused pipeline advanced dialogues regarding RNX-051, a clear development strategy for RNX-011, and an unambiguous goal of realizing maximum long-term value through partnerships and license agreements. The company will continuously keep the market updated on significant progress. For further information, contact: Christian Tange, CEO, Pharma Equity Group A/S, telephone: +45 2948 8417, e-mail: ct@pharmaequitygroup.com Christian Vinding Thomsen, Chairman of the Board, Pharma Equity Group A/S, telephone: +45 2622 7222, e-mail: cvt@loevenlaw.dk About Pharma Equity Group A/S Pharma Equity Group A/S is a listed company on Nasdaq Copenhagen that focuses on early investment in and development of Life Science companies with great potential. The company's strategic focus is to act as an active consolidator within the areas of Pharma, MedTech, and Medical Devices, with a particular eye for Nordic innovation that addresses significant unmet medical needs. Through an actively managed portfolio, which includes the wholly-owned subsidiary Reponex Pharmaceuticals A/S, Pharma Equity Group works to create value by providing capital, strategic management, and industry-specific expertise to its portfolio companies. The goal is to bring groundbreaking healthcare solutions quickly
- ·12.12.2025What do you others think about Otiom possibly being acquired now?2 ääntä PäättynytLiity Sharevilleen nähdäksesi tuloksetMakes sense50%Makes no sense50%Complete disaster0%Other0%
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
19 376
Myynti
Määrä
2 671
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 671 | - | - | ||
| 45 000 | - | - | ||
| 22 866 | - | - | ||
| 17 124 | - | - | ||
| 112 339 | - | - |
Ylin
0,112VWAP
Alin
0,081VaihtoMäärä
0,1 603 293
VWAP
Ylin
0,112Alin
0,081VaihtoMäärä
0,1 603 293
Välittäjätilasto
Dataa ei löytynyt